NDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Apr 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Priority Review
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA (riboflavin 5-phosphate ophthalmic) by Glaukos is 5'-phosphate sodium (vitamin b2) is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. First approved in 2016.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA is a riboflavin 5-phosphate ophthalmic solution administered topically to the eye. It is used in conjunction with UV-A light exposure for corneal collagen crosslinking, a procedure designed to halt the progression of corneal ectasia and keratoconus. The riboflavin acts as a photosensitizer that, when activated by UV-A light, creates covalent bonds between collagen fibers to strengthen corneal tissue.
Peak
At peak lifecycle stage with moderate competitive pressure (30%), the brand team is likely focused on market penetration and maintaining procedure adoption among ophthalmology centers.
Mechanism of Action
5'-phosphate sodium (Vitamin B2) is the precursor of two coenzymes, flavin adenine dinucleotide and flavin mononucleotide, which catalyze oxidation/reduction reactions involved in a number of metabolic pathways. Under the conditions used for corneal collagen cross-linking, riboflavin 5'-phosphate…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on PHOTREXA offers exposure to the specialized ophthalmology market and procedure-based reimbursement models, skills highly valued in specialty care. However, the zero linked job count and peak lifecycle stage suggest this is a stable, mature product with limited expansion opportunities; ideal for professionals seeking stability over rapid growth.
Brand Manager
Worked on PHOTREXA VISCOUS IN DEXTRAN 20%/PHOTREXA at Glaukos? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.